Author profile

Assessing the generalizability of finerenone trial criteria to a British Columbia population with type 2 diabetes in a community endocrinology setting

Background Finerenone is a nonsteroidal mineralocorticoid receptor antagonist that has been shown to lower the risk of cardiovascular and renal events in people with type 2 diabetes and chronic kidney disease.[1-3]... Read More

Challenges to managing type 2 diabetes in British Columbia: Discordant guidelines and limited treatment options

Diabetes is a chronic metabolic disease that is becoming more common in British Columbia, with predicted prevalence rates rising from 8.3% in 2013 to 10.3% in 2020.[1] The complications of diabetes contribute... Read More